NCT04410406View on ClinicalTrials.gov

Moxidectin for LF, Cote d'Ivoire (DOLF)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Lymphatic Filariasis
Interventions
DRUG

Ivermectin

Ivermectin (IVM) 200 µg/kg

DRUG

Diethylcarbamazine

Diethylcarbamazine (DEC) 6mg/kg

DRUG

Albendazole

Albendazole (ABZ) 400 mg

DRUG

Moxidectin

Moxidectin (Mox) 8 mg

Trial Locations (1)

Unknown

Regional Hospital of Agboville, Southern Cote d'Ivoire, Agboville

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

collaborator

Regional Hospital of Agboville, Southern Cote d'Ivoire

UNKNOWN

lead

Washington University School of Medicine

OTHER

NCT04410406 - Moxidectin for LF, Cote d'Ivoire (DOLF) | Biotech Hunter | Biotech Hunter